Eiger BioPharmaceuticals (NasdaqGM: EIGR) is focused on the development of therapies for orphan indications. The Company’s lead candidate is Sarasar (lonafarnib) for the treatment of hepatitis delta virus (HDV) infection. Data readouts in 2016 from three Phase II studies of Sarasar are major catalysts for the Company. Eiger has a diversified development pipeline that includes Exendin (9-39), a glucagon-like peptide 1 (GLP-1) antagonist, for the treatment of hypoglycemic episodes following gastric bypass surgery, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and primary lymphedema. Each of these indications represents a large market opportunity with a serious unmet medical need, as well as an expectation of premium pricing.